Aviragen Therapeutics to Host Conference Call to Report Fourth Quarter and Fiscal Year 2016 Financial Results on September 8,...
September 01 2016 - 8:00AM
Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota
Pharmaceuticals, Inc.), a pharmaceutical company that is developing
the next generation of antivirals, today announced that management
will host a conference call on Thursday, September 8, 2016 at 4:30
p.m. ET to review the Company’s financial results for the three
month period and 2016 fiscal year ended June 30, 2016 and will
provide an update on recent corporate developments. The Company
will issue a press release summarizing its financial results the
same day, prior to the conference call.
In order to participate in the conference call, please dial
(877) 312-5422 (domestic) or (253) 237-1122 (international) and
refer to conference ID number 74878442. The live webcast can be
accessed under the Investors section of the Company’s website at
www.aviragentherapeutics.com.
About Aviragen Therapeutics, Inc.
Aviragen Therapeutics is focused on the discovery and
development of the next generation of direct-acting antivirals to
treat infections that have limited therapeutic options and affect a
significant number of patients globally. The Company has three
product candidates in active clinical development: vapendavir, an
oral treatment for human rhinovirus upper (HRV) respiratory
infections in moderate-to-severe asthmatics currently being
evaluated in the Phase 2b SPIRITUS trial; BTA585, an oral fusion
protein inhibitor that has received Fast Track designation by
the U.S. FDA, in Phase 2 development for the treatment
and prevention of respiratory syncytial virus (RSV) infections; and
BTA074, a topical antiviral treatment in Phase 2 development for
condyloma caused by human papillomavirus types 6 & 11. For
additional information about the Company, please
visit www.aviragentherapeutics.com.
Contacts:
Mark Colonnese
Executive Vice President and Chief Financial Officer
Aviragen Therapeutics, Inc.
(678) 221-3381
mcolonnese@aviragentherapeutics.com
Beth DelGiacco
Stern Investor Relations, Inc.
(212) 362-1200
beth@sternir.com
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Apr 2024 to May 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From May 2023 to May 2024